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BACKGROUND: Interventions that improve muscle function may slow decline in physical function and
disability in later life. Recent evidence suggests that inhibition of the renin-angiotensin-aldosterone system
may maintain muscle function. We evaluated the effect of aldosterone blockade on physical performance in
functionally impaired older people without heart failure.
METHODS: In this parallel-group, double-blind, randomized, placebo-controlled trial, community-dwelling
participants aged 65 years with self-reported problems with activities of daily living were randomized to
receive 25 mg spironolactone or identical placebo daily for 20 weeks. The primary outcome was change in
6-minute walking distance over 20 weeks. Secondary outcomes were changes in Timed Up and Go test,
Incremental Shuttle Walk Test, Functional Limitation Proﬁle, EuroQol EQ-5D, and Hospital Anxiety and
Depression Scale over 20 weeks.
RESULTS: Participants’mean (standard deviation) age was 75 (6) years. Of the 93% of participants (112/120)
who completed the study, 106 remained on medication at 20 weeks. There was no signiﬁcant difference in
change in 6-minute walking distance at 20 weeks between the spironolactone and placebo groups (mean
change, 3.2 m; 95% conﬁdence interval, 28.9 to 22.5; P ¼ .81). Quality of life improved signiﬁcantly at
20 weeks, with an increase in EuroQol EQ-5D score of 0.10 (95% conﬁdence interval, 0.03-0.18; P < .01)
in the spironolactone group relative to the placebo group. There were no signiﬁcant differences in between-
group change for other secondary outcomes.
CONCLUSIONS: Spironolactone was well tolerated but did not improve physical function in older people
without heart failure. Quality of life improved signiﬁcantly, and the possible mechanisms for this require
further study.
 2013 Elsevier Inc.  The American Journal of Medicine (2013)
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Open access under CC BY-NC-ND license.Decline in physical function with age is a major public health
issue because it is strongly associated with disability in later
life.1 Recent evidence from observational studies suggests that
inhibition of the renin-angiotensin-aldosterone system may
improve muscle function in older people.2 Subsequent
randomized controlled trials with angiotensin-converting
enzyme (ACE) inhibitors have shownmixed results. The use of
the ACE inhibitor perindopril improved walking distance in
functionally impaired older people without heart failure.3
However, in another study in older patients with a high
cardiovascular risk proﬁle, ACE inhibitors did not improve
muscle strength or physical performance after 6 months.4
Burton et al Spironolactone and Exercise Capacity 591Elevated levels of angiotensin II or aldosterone are associated
with increased skeletal muscle wasting and decline in skeletal
muscle function.5 ACE inhibitors block local aldosterone
release temporarily,6 so blocking aldosterone receptors with
spironolactone may be a more effective aldosterone-related
target to counter the effects of physical impairment with age.CLINICAL SIGNIFICANCE
 Interventions that improve muscle func-
tion, such as inhibitors of the renin-
angiotensin-aldosterone system, may
slow decline in physical function and
reduce disability in older adults.
 In this prospective randomized trial,
spironolactone did not improve physical
function in older adults without heart
failure.
 The possibility that spironolactone may
have favorable effects on quality of life
requires further study.Spironolactone could improve skel-
etal muscle function by increasing
the skeletal muscle magnesium
content and increasing the levels of
Naþ/Kþ pumps required for muscle
contractility,7,8 reducing the proin-
ﬂammatory cytokine response as-
sociated with aging muscle,9,10 and
improving vascular endothelial
function and skeletal muscle in
people without heart failure.11,12
We therefore designed a clinical
trial to examine whether spi-
ronolactone could improve phys-
ical performance in functionally
impaired older people without
heart failure.
MATERIALS AND METHODSStudy Design and Participants
This was a prospective, parallel-group, double-blind,
randomized, placebo-controlled trial. The study was con-
ducted from November 2008 to April 2011. Patients were
recruited from Primary Care using the East of Scotland
Node of the Scottish Primary Care Research Network and
from Medicine for the Elderly clinical services in NHS
Tayside, Scotland. All participants provided written
informed consent. Research ethics approval was granted
by the Tayside Committee on Medical Research Ethics
(REC08/S1402/34), and the study conformed to the princi-
ples of the Declaration of Helsinki.
Patients aged 65 years with self-reported problems
with activities of daily living were eligible. Daily living
abilities were not objectively scored. Patients were ex-
cluded if they had a clinical diagnosis of heart failure
(according to European Society of Cardiology guidelines),
left ventricular systolic dysfunction, systolic blood pressure
<100 mm Hg, serum potassium >5.0 mmol/L, serum
sodium <130 mmol/L, serum creatinine >200 mmol/L,
estimated glomerular ﬁltration rate <30 mL, Addison’s
disease, or Mini-Mental-State Examination score <20/30.
Patients were excluded if they were wheelchair bound,
a resident in institutional care, or already taking an ACE
inhibitor or angiotensin receptor blocker.
At the baseline screening visit, participants underwent
a full clinical examination and an echocardiogram was
performed to assess left ventricular systolic function using
the SonoSite TITAN ultrasound system (SonoSite Inc,
Bothell, Wash). A subjective assessment was made of left
ventricular systolic function. This has good reproducibilitycompared with other methods of echocardiography, such as
contrast ventriculography.13 Echocardiography was re-
peated at 20 weeks to rule out the development of occult left
ventricular systolic dysfunction during the study period.Randomization
Randomization of medication was
performed by Tayside Pharma-
ceuticals (Dundee, UK) using
a computer-generated, random-
number table to conceal treatment
allocation. Medication bottles
were labeled with sequential par-
ticipant numbers. Randomization
codes were held by Tayside
Pharmaceuticals. The researcher
who enrolled the participants and
distributed the medication had
no access to randomization code.
Participants were randomized to
receive spironolactone or placebo
for 20 weeks. The starting dose
was 12.5 mg of spironolactone or
placebo and was increased after 2weeks to reach a maximum dose of 25 mg of spi-
ronolactone or placebo.Outcome Measures
The primary outcome was change in 6-minute walking
distance over 20 weeks. The 6-minute walk test is a measure
of submaximal exercise performance and has been validated
as a safe, reliable, and repeatable measure of functional
status and endurance performance in elderly people.14 The
test was performed over a 25-m course using their usual
walking aids if required. Standardized encouragement was
given at regular intervals. The 6-minute walk test was per-
formed at baseline and 10 and 20 weeks. Secondary
outcomes were changes in physical function, self-reported
function, mood, and quality of life over 20 weeks. The
Incremental Shuttle Walk Test is a safe, reliable, and stan-
dardized exercise test of functional capacity in older
people.15,16 Participants walked over a 10-m course, and
walking speed was externally controlled by beeping signals
from an audio cassette. The Timed Up and Go test measures
the time taken to rise from a chair, walk 3 m, and return to
sit in the chair. The test has been widely used in measuring
clinically signiﬁcant changes in mobility in older frail
people and tests explosive muscle power rather than
endurance.17,18
The EuroQol questionnaire measures self-reported health-
related quality of life and is divided into 2 parts. The EQ-5D
contains questions covering 5 domains: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
The responses are converted to an overall score from 0.59
to 1 using a table of weighted values. The EuroQol Visual
592 The American Journal of Medicine, Vol 126, No 7, July 2013Analogue Scale (EQ-VAS) is a 20-cm visual analogue scale
that allows patients to score their overall health state for that
day from 0 (worst) to 100 (best). The Hospital Anxiety and
Depression Scale (HADS) measures change in psychologic
state. It is a validated tool in older people with chronic
illness that minimizes reliance on somatic symptoms when
evaluating depression and anxiety.19 The Functional Limi-
tation Proﬁle, a modiﬁed version of the Sickness Impact
Proﬁle, is a valid self-report measure of physical, psycho-
logic, and social function.20 The test has been successfully
used to measure the effect of interventions in older people.21
Secondary outcomes were measured at 10 and 20 weeks.
Other Measurements
Blood samples were obtained to measure serum creatinine,
magnesium, urea, and electrolyte levels at baseline and 2, 5,Figure 1 Participant ﬂow through the study.
ADL ¼ activities of daily living; eGFR ¼
SBP ¼ systolic blood pressure.10, and 20 weeks. Samples were analyzed in the Depart-
ment of Biochemical Medicine, Ninewells Hospital, using
the Roche Modular Analytics system (Roche Diagnostics,
Lewes, East Sussex, UK). Plasma aldosterone and B-type
natriuretic peptide were measured at baseline and 20 weeks
by the Department of Clinical Pharmacology, University of
Dundee, using radioimmunoassays with intra-assay coefﬁ-
cient of variation of 13.2% and 5.5%, respectively. Postural
blood pressure was measured at baseline and 10 and 20
weeks.Statistical Analysis
From previous studies in similar populations, we anticipated
the mean (standard deviation) 6-minute walking distance to
be 300 m with a standard deviation of 50 m.3 We estimatedACE ¼ angiotensin-converting enzyme;
estimated glomerular ﬁltration rate;
Table 1 Baseline Characteristics
Spironolactone
(n ¼ 60)
Placebo
(n ¼ 60) P
Mean age (y) (SD) 75.1 (5.6) 74.2 (6.5) .43
Male sex 31 (52.5%) 34 (56.7%) .65
Weight (kg) 78.2 (14.0) 77.0 (18.7) .69
Height (cm) 168 (7) 165 (10) .15
MMSE (median, IQR) 29 (2) 29 (2) .67
Walking aid
None 37 (63%) 46 (77%) .10
1 stick 17 (29%) 11 (18%) .18
2 sticks 2 (3%) 1 (2%) .18
Zimmer frame 2 (3%) 0 .15
Triwheel walker 1 (2%) 2 (3%) .57
Comorbidities
Hypertension 19 (32%) 16 (27%) .50
Ischemic heart disease 8 (14%) 7 (12%) .76
Peripheral vascular
disease
3 (5%) 2 (3%) .63
Myocardial infarction 2 (3%) 1 (2%) .55
Diabetes mellitus 5 (9%) 7 (12%) .56
COPD 10 (17%) 13 (22%) .52
Stroke/TIA 5 (9%) 4 (7%) .71
Parkinson’s disease 6 (10%) 1 (2%) .05
Osteoarthritis 24 (41%) 30 (50%) .31
Medication
Loop diuretics 3 (5%) 3 (5%) 1.00
Thiazide diuretics 8 (13%) 11 (18%) .43
Aspirin 17 (29%) 18 (30%) .71
Burton et al Spironolactone and Exercise Capacity 593that a ﬁnal sample size of 88 participants (44 per group)
would have 80% power (a ¼ 0.05, 2-tailed) to detect a 30-m
difference in walking distance at 20 weeks.22 In anticipation
of a dropout rate of 27%, as seen in our previous study,
a projected sample size of 120 participants was required to
yield 88 completing participants over 20 weeks.
All data entry, data management, and main outcome
analyses were performed independently by the Robertson
Centre for Biostatistics, University of Glasgow. Data were
analyzed using SAS version 9.2 (SAS Institute Inc, Cary,
NC). Analyses were performed only after all data were
entered and the database had been locked. Analyses of the
outcomes were performed before breaking the treatment
codes. Exploratory subgroup analyses were performed by the
investigators using SPSS version 18.0 (SPSS Inc, Chicago,
Ill) after treatment codes were broken. Differences between
groups at baseline were compared using the Student t test.
By using intention-to-treat analysis, differences between
treatment groups for the outcomes were assessed by Student
t test. Analysis of covariance models were used to compare
the change in outcomes across the treatment groups at 10
and 20 weeks. To compensate for effect of regression to the
mean, we analyzed the change in outcomes using analysis of
covariance models and baseline measurements of physical
function and age as covariates. As a safeguard against the
inﬂuence of any data missing at random, analysis of the
primary outcome also was performed using multiple impu-
tation (10 iterations) to replace missing data.Statins 15 (25%) 9 (15%) .17
Calcium channel blockers 10 (17%) 6 (10%) .30
Beta-blockers 3 (5%) 5 (8%) .53
Bronchodilators 3 (5%) 5 (8%) .53
Inhaled steroids 4 (3%) 4 (3%) 1.00
Total no. of medications
(median, IQR)
5 (3) 5 (3) .97
BP ¼ blood pressure; COPD ¼ chronic obstructive pulmonary disease;
IQR ¼ interquartile range; MMSE ¼ Mini-Mental State Examination;
SD ¼ standard deviation; TIA ¼ transient ischemic attack.
Note: Except where mentioned, values are mean and SD.RESULTS
A total of 3398 participants were assessed for eligibility by
screening their medical case notes. Of these, 571 (17%)
were found to be ineligible. The remaining 2827 were
contacted by letter, and 87% (2460/2827) failed to reply.
The 367 subjects who replied were brieﬂy screened by
telephone; of these, 120 were randomized and 112 of 120
(93%) completed the study. Figure 1 shows patient ﬂow
through the study and reasons for withdrawal. No partici-
pant had developed left ventricular systolic dysfunction at
20 weeks.
The median (range) compliance of medication derived
from tablet counting was 99% (44%-121%) in the spi-
ronolactone group and 99% (51%-110%) in the placebo
group. A total of 89% and 94% of participants had compli-
ance >85% in the spironolactone and placebo groups,
respectively.
All participants were of white European origin. Groups
were well matched at baseline (Table 1) except that partic-
ipants in the spironolactone group had lower mean serum
aldosterone levels and a higher proportion of participants
with Parkinson’s disease compared with the placebo group.Primary Outcome
The mean 6-minute walking distance in the spironolactone
group increased by 30.5 m (9.1%) compared with 33.7 m(9.8%) in the placebo group at 20 weeks. Unadjusted
comparison of the change in 6-minute walking distance
between baseline and follow-up showed no signiﬁcant
improvement in the treatment group compared with placebo
at 20 weeks with a between group difference of 3.2 m
(95% conﬁdence interval [CI], 28.9 to 22.5; P ¼ .81).
There was no signiﬁcant difference between the groups in
distance walked at 10 weeks (Table 2). Adjusted analyses
also show no signiﬁcant change in 6-minute walking
distance between baseline and 20 weeks (Table 3).Secondary Outcome Measures
The changes in secondary measures from baseline are
shown in Table 2. Secondary measures of muscle function
and physical function (Timed Up and Go test, Incremental
Shuttle Walk Test, and Functional Limitation Proﬁle)
Table 2 Unadjusted Changes in Outcome Measures from Baseline
Outcome Measure Time Spironolactone Placebo Difference Between Groups (95% CI) P Value
6-min walking distance (m) 10 wk 27.4 27.5 0.1 (22.9 to 22.7) .99
20 wk 30.5 33.7 3.2 (28.9 to 22.5) .81
Timed Up and Go test (s) 10 wk 1.4 1.2 0.2 (1.3 to 0.9) .72
20 wk 1.3 1.3 0.04 (1.3 to 1.3) .95
ISWT distance (m) 10 wk 13.9 17.6 3.7 (21.4 to 27.5) .72
20 wk 25.4 22.4 3.1 (21.4 to 27.5) .81
FLP total score 10 wk 16 17 1 (45 to 47) .97
20 wk 14 22 8 (49 to 64) .78
EuroQol EQ-5D 10 wk 0.05 0.01 0.04 (0.03 to 0.11) .22
20 wk 0.11 0.01 0.10 (0.03-0.18) .006
EuroQol EQ-VAS 10 wk 4.2 2.8 1.5 (4.3 to 7.2) .62
20 wk 0.3 1.6 1.9 (8.3 to 4.5) .55
HADS-D score 10 wk 1.11 0.25 0.84 (1.58 to 0.09) .03
20 wk 0.23 0.04 0.20 (0.97 to 0.58) .62
HADS-A score 10 wk 0.11 0.23 0.12 (0.83 to 1.09) .80
20 wk 0.33 0.45 0.78 (0.17 to 1.69) .11
EQ-VAS ¼ EuroQol Visual Analogue Scale; HADS ¼ Hospital Anxiety and Depression Scale; ISWT ¼ Incremental Shuttle Walk Test; FLP ¼ Functional
Limitation Proﬁle.
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with placebo at follow-up. There was a signiﬁcant difference
in the EQ-5D utility score of 0.10 (95% CI, 0.03-0.18) in the
spironolactone group compared with the placebo group at
20 weeks (P < .01). This comparison remained signiﬁcant
even after adjustment for baseline EQ-5D utility score and
age as covariates (0.07; 95% CI, 0-0.13; P ¼ .04). Post hoc
subgroup analysis showed a signiﬁcant improvement in pain
(P < .01) within the EQ-5D score domains, with joint pain
due to osteoarthritis reported as the main cause of pain.
There was a signiﬁcant decline in the unadjusted HADS-D
score of 0.84 in the spironolactone group compared with the
placebo group at 10 weeks (P¼ .03), that is, an improvement
in mood. However, this difference did not persist at
20 weeks, and adjustment for baseline HADS score rendered
the between-group difference in change at 10 weeks
nonsigniﬁcant: 0.57 (95% CI, 1.27 to 0.12; P ¼ .11).Other Measures
There was a signiﬁcant decline in systolic (7mmHg, P¼ .02)
and diastolic (5 mm Hg, P ¼ .03) blood pressures in the
spironolactone group at 10 weeks compared with the placebo
group. Nonsigniﬁcant changes were seen in both systolicTable 3 Change in 6-Minute Walking Distance from Baseline to 20 W
Unadjusted for baseline 6-min walking distance (m)
Adjusted for baseline 6-min walking distance (m)
Adjusted for baseline 6-min walking distance (m) and age (y)
Multiple imputation adjusted for baseline 6-min walking distance (m)
Multiple imputation adjusted for baseline 6-min walking distance (m) a
CI ¼ conﬁdence interval.(6 mm Hg, P ¼ .06) and diastolic (3 mm Hg, P ¼ .10) blood
pressures at 20 weeks. There was no signiﬁcant decline in
postural blood pressure with spironolactone compared with
placebo at 20 weeks.
Changes in blood test results are summarized in
Table 4. As expected, spironolactone was associated with
a signiﬁcant increase in serum potassium, serum creatinine,
and serum aldosterone, with spironolactone at 20 weeks in
keeping with aldosterone blockade.Adverse Events
Adverse events that led to withdrawal of participants are
shown in Figure 1. Of the participants taking spironolactone,
2 developed a rash and 1 had gynecomastia. Medication was
discontinued in 4 patients in the spironolactone group
(serum sodium <130 mmol/L in 2, decrease in systolic
blood pressure to <100 mm Hg in 1, skin rash in 1) and 2
patients in the placebo group (skin rash in 1 and persistent
dizziness in 1). Five participants (2 in the spironolactone
group and 3 in the placebo group) were unable to tolerate up-
titration of dose at 2 weeks because of an increase in serum
potassium (>5.0 mmol/L but <5.5 mmol/L). All 5 remained
on 12.5 mg of spironolactone/placebo for the duration of theeeks, Using Models for Adjustment
Between Group Difference (95% CI) P Value
3.2 (28.9 to 22.5) .81
4.7 (29.9 to 20.5) .71
3.7 (28.6 to 21.2) .77
5.0 (28.5 to 18.5) .67
nd age (y) 6.1 (29.7 to 17.6) .62
Table 4 Changes in Blood Test Results at 20 Weeks from Baseline
Test Spironolactone (95% CI) Placebo (95% CI) P Value
Serum potassium (mmol/L) 0.2 (0.1-0.3) 0.0 (0.1 to 0.1) .01
Serum sodium (mmol/L) 0.9 (1.6 to 0.3) 0.6 (1.2 to 0.1) .43
Urea (mmol/L) 0.5 (0.2-0.9) 0.4 (0.0-0.8) .67
Serum creatinine (mmol/L) 6.7 (6.1-9.4) 2.5 (0.2 to 5.2) .03
Serum magnesium (mmol/L) 0.02 (0.03 to 0.01) 0.02 (0.03 to 0.00) .55
Aldosterone (pg/mL) 136.9 (101.3-172.7) 20.1 (15.9 to 56.2) .001
B-type natriuretic peptide (pg/mL) 4.2 (11.6 to 3.3) 1.2 (8.6 to 6.4) .57
CI ¼ conﬁdence interval.
Burton et al Spironolactone and Exercise Capacity 595study without any adverse effect. No participant in either
group developed a potassium level >5.5 mmol/L.DISCUSSION
This study found that spironolactone did not improve
physical performance, as measured by change in 6-minute
walk test at 20 weeks, compared with placebo. The min-
imum clinically important difference of 30 m falls outside
the 95% CIs around our results, making it highly unlikely
that we have missed a clinically important improvement in
the 6-minute walk distance. The minimum clinically im-
portant difference in 6-minute walking distance in older
people without heart failure may be as low as 20 m.22 Even
this more conservative value falls outside the 95% CIs
derived from the imputed data set. The lack of change in the
Timed Up and Go test, Incremental Shuttle Walk Test, and
Functional Limitation Proﬁle (a self-reported measure of
physical function) with spironolactone reinforces our neutral
ﬁnding with the primary outcome. The ﬁnal sample size
exceeded the required target sample size because of a lower
than expected dropout rate, which was sufﬁcient to detect
a clinical effect in the primary outcome. Our results were
consistent with the Randomized Aldosterone Antagonism in
Heart Failure with Preserved Ejection Fraction trial, in
which no signiﬁcant improvement was seen in 6-minute
walk distance with aldosterone antagonist eplenerone in
patients with preserved left ventricular ejection fraction.23
Spironolactone signiﬁcantly improved quality of life with
a between-group difference of 0.10 in the EQ-5D compared
with placebo, a value that exceeds the minimally clinically
important difference of 0.08.24 However, because this was
a secondary end point, this observation must be interpreted
with caution. The improvement in the EQ-5D score in the
spironolactone group was not matched by a similar im-
provement in the EQ-VAS. This is in keeping with ﬁndings
from other studies that found that EQ-VAS is less sensitive
to change than EQ-5D.25
A major strength of this study was that the effect of
aldosterone antagonism was tested in the absence of ACE
inhibition. Spironolactone may indeed have a role in im-
proving physical performance, but most of the supporting
evidence for this comes from studies in animals or in pa-
tients with chronic heart failure, where improvements inphysical performance could be attributed to improvements
in cardiac function by reducing myocyte apoptosis and
improving left ventricular ejection fraction.26 Previous
work showed that ACE inhibitors improve exercise perfor-
mance in older people both with and without chronic heart
failure.3,27 However, ACE inhibitors did not improve
physical performance in patients with cardiovascular risk
factors.4 It is possible that targeting other components of the
renin-angiotensin-aldosterone system (eg, angiotensin II)
may improve muscle function. There also is a lack of
evidence to suggest whether improvement in physical
performance can be sustained long-term with ACE inhibi-
tion. Observational studies show that aldosterone levels
eventually return to baseline with long-term ACE inhibi-
tion.26 Therefore, it could be hypothesized that aldosterone
antagonism may be beneﬁcial to physical performance in the
longer term when used in conjunction with ACE inhibition.
However, this theory would require further research.
Despite the lack of effect on physical performance, there
was a signiﬁcant improvement in health-related quality of
life in the spironolactone group. However, these ﬁndings
must be interpreted with caution, and further trials using
health-related quality of life as the primary end point are
required to conﬁrm this observation. Other work with spi-
ronolactone has shown improvement in quality of life in
association with improvement in physical performance or
cardiac symptoms in patients with chronic heart failure.26,28
A similar improvement in quality of life, as measured by
improvement in EQ-5D score, was seen in our previous
study with ACE inhibitors in older people without heart
failure.3 This suggests a potential common mechanism
involving inhibition of the renin-angiotensin-aldosterone
system and improvements in health-related quality of life;
however, further research is required to further explore this
hypothesis.
Improvements in health-related quality of life may have
occurred because of other pharmacologic effects of spi-
ronolactone. Post hoc analysis showed a signiﬁcant
improvement in the pain domain of the EQ-5D score. Joint
pain from osteoarthritis was the most common cause of
pain. No previous studies have reported a reduction in pain
with spironolactone. However, it is feasible that spi-
ronolactone may have anti-inﬂammatory effects. Aldoste-
rone is proinﬂammatory, making it likely that by blocking
596 The American Journal of Medicine, Vol 126, No 7, July 2013aldosterone spironolactone may beneﬁcially affect inﬂam-
mation and pain.29 Spironolactone also increases plasma
cortisol, a potentially anti-inﬂammatory substance.30
Finally, in patients with chronic arthritis, spironolactone
markedly suppressed the transcription of several proin-
ﬂammatory cytokines, including the release of tumor
necrosis factor-a, interleukin-1, and interleukin-6.10 Our
observation suggests possible wider pharmacologic beneﬁts
of spironolactone in functionally impaired older people and
merits further research.
Study Limitations
First, the use of self-reported problems in activities of daily
living may have introduced subject bias. The use of physical
performance tests, such as the Sit to Stand test or the short
physical performance battery test, may have provided
a more objective method to measure participants’ functional
state. Second, although changes in serum potassium, creat-
inine, and aldosterone were consistent with known physio-
logic effects of aldosterone blockade.28 It is possible that
a higher dose of spironolactone may be required to inﬂuence
the pathophysiologic effects of aging on skeletal muscle to
a degree that improves physical performance. The low rate
of adverse events with 25 mg of spironolactone provides
encouragement for the potential use of a higher dose of
spironolactone in similar older populations. Third, it is
possible that a treatment duration of greater than 20 weeks is
required to elicit changes in physical function. In the
Randomized Aldactone Evaluation Study trial, the phar-
macologic effects of spironolactone on morbidity and
mortality in patients with chronic heart failure was shown
over a follow-up period of 24 months.28 Finally, the mean
baseline 6-minute walk distance was higher than in previous
studies involving frail older people.3 Therefore, our study
population may not have been the subgroup most likely to
beneﬁt.
CONCLUSIONS
Interventions that improve muscle function, such as inhibi-
tors of the renin-angiotensin-aldosterone system, may slow
decline in physical function and reduce disability in older
people. In this prospective randomized controlled trial,
spironolactone did not improve physical performance in
functionally impaired older people without heart failure,
despite being well tolerated with few side effects. The
possibility that spironolactone may have favorable effects
on quality of life requires further research.
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